Treatment of allergic rhinitis using mobile technology with real‐world data: The <scp>MASK</scp> observational pilot study

  • J. Bousquet
    Contre les MAladies Chroniques Pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site MACVIA‐France Montpellier France
  • P. Devillier
    Laboratoire de Pharmacologie Respiratoire UPRES EA220 Pôle des Maladies Respiratoires Hôpital Foch Suresnes ‐ Université Versailles Saint‐Quentin Versailles France
  • S. Arnavielhe
    Kyomed Montpellier France
  • A. Bedbrook
    Contre les MAladies Chroniques Pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site MACVIA‐France Montpellier France
  • G. Alexis‐Alexandre
    EZY Montpellier France
  • M. van Eerd
    Peercode BV Gerdermalsen The Netherlands
  • R. Murray
    Medical Communications Consultant MedScript Ltd Dundalk Ireland
  • G. W. Canonica
    Allergy and Respiratory Diseases Department of Internal Medicine IRCCS San Martino‐IST‐University of Genoa Genoa Italy
  • M. Illario
    Division for Health Innovation Campania Region and Federico II University Hospital Naples (R&D and DISMET) Naples Italy
  • E. Menditto
    Center of Pharmacoeconomics CIRFF University of Naples Federico II Naples Italy
  • G. Passalacqua
    Allergy and Respiratory Diseases Department of Internal Medicine IRCCS San Martino‐IST‐University of Genoa Genoa Italy
  • C. Stellato
    Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana” University of Salerno Salerno Italy
  • M. Triggiani
    Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana” University of Salerno Salerno Italy
  • P. Carreiro‐Martins
    Servicio de Imunoalergologia EPE – Nova Medical School Respiratory Research Group CEDOC Centro Hospitalar de Lisboa Central Lisbon Portugal
  • J. Fonseca
    Faculdade de Medicina Center for Health Technology and Services Research‐CINTESIS Universidade do Porto Porto Portugal
  • M. Morais Almeida
    Rhinology Unit & Smell Clinic ENT Department Hospital Clinic Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES University of Barcelona Barcelona Spain
  • L. Nogueira‐Silva
    Department of Internal Medicine Center for Health Technology and Services Research—CINTESIS Centro Hospitalar Sao Joao Porto Portugal
  • A. M. Pereira
    Allergy Unit CUF Porto Instituto & Hospital Porto Portugal
  • A. Todo Bom
    Imunoalergologia Centro Hospitalar Universitario de Coimbra Faculty of Medicine University of Coimbra Coimbra Portugal
  • I. Bosse
    Allergist La Rochelle France
  • D. Caimmi
    CHU de Montpellier UPMC, Paris 06 UMR‐S 1136, IPLESP, Equipe EPAR Sorbonne Universités Paris France
  • P. Demoly
    CHU de Montpellier UPMC, Paris 06 UMR‐S 1136, IPLESP, Equipe EPAR Sorbonne Universités Paris France
  • J. F. Fontaine
    Allergist Reims France
  • J. Just
    Allergology Department Centre de l'Asthme et des Allergies Hôpital d'Enfants Armand‐Trousseau – INSERM UMRS 1136, UPMC Univ Paris 06 – Institut Pierre Louis d'Epidémiologie et de Santé Publique Equipe EPAR Sorbonne Universités Paris France
  • G. L. Onorato
    Contre les MAladies Chroniques Pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site MACVIA‐France Montpellier France
  • M. L. Kowalski
    Department of Immunology, Rheumatology and Allergy Medical University of Lodz Lodz Poland
  • P. Kuna
    Division of Internal Medicine Asthma and Allergy Barlicki University Hospital Medical University of Lodz Lodz Poland
  • B. Samolinski
    Department of Prevention of Environmental Hazards and Allergology Medical University of Warsaw Warsaw Poland
  • J. M. Anto
    ISGLoBAL Centre for Research in Environmental Epidemiology (CREAL) Barcelona Spain
  • J. Mullol
    Rhinology Unit & Smell Clinic ENT Department Hospital Clinic Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES University of Barcelona Barcelona Spain
  • A. Valero
    Pneumology and Allergy Department Hospital Clınic Clinical & Experimental Respiratory Immunoallergy IDIBAPS, CIBERES University of Barcelona Barcelona Spain
  • P. V. Tomazic
    Department of ENT Medical University of Graz Graz Austria
  • K. C. Bergmann
    Comprehensive Allergy‐Centre‐Charité Department of Dermatology and Allergy Global Allergy and Asthma European Network (GA<sup>2</sup>LEN) Charité Universitatsmedizin Berlin Berlin Germany
  • T. Keil
    Institute of Social Medicine, Epidemiology and Health Economics Charité—Universitatsmedizin Berlin Germany
  • L. Klimek
    Center for Rhinology and Allergology Wiesbaden Germany
  • R. Mösges
    Institute of Medical Statistics and Computational Biology Medical Faculty University of Cologne Cologne Germany
  • S. Shamai
    Institute of Medical Statistics and Computational Biology Medical Faculty University of Cologne Cologne Germany
  • T. Zuberbier
    Comprehensive Allergy‐Centre‐Charité Department of Dermatology and Allergy Global Allergy and Asthma European Network (GA<sup>2</sup>LEN) Charité Universitatsmedizin Berlin Berlin Germany
  • E. Murphy
    Newcastle OHS The Newcastle upon Tyne NHS Foundation Hospitals Trust Newcastle upon Tyne UK
  • P. McDowall
    Newcastle OHS The Newcastle upon Tyne NHS Foundation Hospitals Trust Newcastle upon Tyne UK
  • D. Price
    Observational and Pragmatic Research Institute Singapore City Singapore
  • D. Ryan
    Allergy and Respiratory Research Group Usher Institute of Population Health Sciences and Informatics University of Edinburgh Edinburgh UK
  • A. Sheikh
    Asthma UK Centre for Applied Research Centre of Medical Informatics Usher Institute of Population Health Sciences and Informatics The University of Edinburgh Edinburgh UK
  • N. H. Chavannes
    Department of Public Health and Primary Care Leiden University Medical Center Leiden The Netherlands
  • W. J. Fokkens
    Department of Otorhinolaryngology Academic Medical Centre Amsterdam The Netherlands
  • V. Kvedariene
    Clinic of Infectious, Chest Diseases, Dermatology and Allergology Vilnius University Vilnius Lithuania
  • A. Valiulis
    Vilnius University Clinic of Children's Diseases and Public Health Institute Vilnius Lithuania
  • C. Bachert
    ENT Department Upper Airways Research Laboratory Ghent University Hospital Ghent Belgium
  • P. W. Hellings
    Euforea Brussels Belgium
  • I. Kull
    Department of Clinical Science and Education Sodersjukhuset Karolinska Institutet Stockholm Sweden
  • E. Melen
    Department of Clinical Science and Education Sodersjukhuset Karolinska Institutet Stockholm Sweden
  • M. Wickman
    Sodersjukhuset Sachs' Children and Youth Hospital Stockholm Sweden
  • C. Bindslev‐Jensen
    Department of Dermatology and Allergy Centre Odense Research Center for Anaphylaxis (ORCA) Odense University Hospital Odense Denmark
  • E. Eller
    Department of Dermatology and Allergy Centre Odense Research Center for Anaphylaxis (ORCA) Odense University Hospital Odense Denmark
  • T. Haahtela
    Skin and Allergy Hospital Helsinki University Hospital Helsinki Finland
  • N. G. Papadopoulos
    Center for Pediatrics and Child Health Institute of Human Development Royal Manchester Children's Hospital University of Manchester Manchester UK
  • I. Annesi‐Maesano
    EPAR U707 INSERM Paris France
  • M. Bewick
    i Q4U Consultants Ltd London UK
  • S. Bosnic‐Anticevich
    Woolcock Institute of Medical Research University of Sydney Sydney NSW Australia
  • A. A. Cruz
    ProAR—Nucleo de Excelencia em Asma Federal University of Bahia Salvador Brazil
  • G. De Vries
    Peercode BV Gerdermalsen The Netherlands
  • B. Gemicioglu
    Department of Pulmonary Diseases Cerrahpasa Faculty of Medicine Istanbul University Istanbul Turkey
  • D. Larenas‐Linnemann
    Center of Excellence in Asthma and Allergy Hospital Médica Sur Mexico City Mexico
  • D. Laune
    Kyomed Montpellier France
  • E. Mathieu‐Dupas
    Kyomed Montpellier France
  • R. E. O'Hehir
    Department of Allergy, Immunology and Respiratory Medicine Alfred Hospital and Central Clinical School Monash University Melbourne Vic. Australia
  • O. Pfaar
    Center for Rhinology and Allergology Wiesbaden Germany
  • F. Portejoie
    Contre les MAladies Chroniques Pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site MACVIA‐France Montpellier France
  • V. Siroux
    INSERM Universite Grenoble Alpes IAB U 1209 Team of Environmental Epidemiology Applied to Reproduction and Respiratory Health Université Joseph Fourier Grenoble France
  • O. Spranger
    Global Allergy and Asthma Platform GAAPP Vienna Austria
  • E. Valovirta
    Department of Lung Diseases and Clinical Allergology Terveystalo Allergy Clinic University of Turku Turku Finland
  • O. VandenPlas
    Department of Chest Medicine Centre Hospitalier Universitaire UCL Namur Université Catholique de Louvain Yvoir Belgium
  • A. Yorgancioglu
    Department of Pulmonology Celal Bayar University Manisa Turkey

抄録

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Large observational implementation studies are needed to triangulate the findings from randomized control trials as they reflect “real‐world” everyday practice. In a pilot study, we attempted to provide additional and complementary insights on the real‐life treatment of allergic rhinitis (AR) using mobile technology.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A mobile phone app (<jats:italic>Allergy Diary</jats:italic>, freely available in Google Play and Apple App stores) collects the data of daily visual analog scales (<jats:styled-content style="fixed-case">VAS</jats:styled-content>) for (i) overall allergic symptoms, (ii) nasal, ocular, and asthma symptoms, (iii) work, as well as (iv) medication use using a treatment scroll list including all medications (prescribed and over the counter (<jats:styled-content style="fixed-case">OTC</jats:styled-content>)) for rhinitis customized for 15 countries.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 2871 users filled in 17 091 days of <jats:styled-content style="fixed-case">VAS</jats:styled-content> in 2015 and 2016. Medications were reported for 9634 days. The assessment of days appeared to be more informative than the course of the treatment as, in real life, patients do not necessarily use treatment on a daily basis; rather, they appear to increase treatment use with the loss of symptom control. The <jats:italic>Allergy Diary</jats:italic> allowed differentiation between treatments within or between classes (intranasal corticosteroid use containing medications and oral H1‐antihistamines). The control of days differed between no [best control], single, or multiple treatments (worst control).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>This study confirms the usefulness of the <jats:italic>Allergy Diary</jats:italic> in accessing and assessing everyday use and practice in AR. This pilot observational study uses a very simple assessment (<jats:styled-content style="fixed-case">VAS</jats:styled-content>) on a mobile phone, shows novel findings, and generates new hypotheses.</jats:p></jats:sec>

収録刊行物

  • Allergy

    Allergy 73 (9), 1763-1774, 2018-03-22

    Wiley

被引用文献 (3)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ